Guillain–Barré syndrome

Jump to: navigation, search
Pronounced ghee-yan bah-ray and named after three French neurologists who described the condition in two soldiers in 1916.

Guillain-Barre Syndrome (GBS) is an autoimmune disease where the body’s immune system begins to attack the peripheral nervous system. Antibodies and lymphocytes attack and damage the peripheral nerves causing weakness/paralysis (motor nerves affected) and/or abnormal sensations and pain (sensory nerves affected).

It can present in many different ways making it difficult to diagnose in the early stages. First symptoms include varying degrees of weakness or tingling sensations in the legs. In many cases this spreads to the upper body and in severe cases leads to almost total paralysis. GBS can be dangerous if the muscle weakness affects the chest muscles responsible for breathing.

The symptoms can occur quite rapidly over hours to days or slowly over weeks. Most patients reach peak weakness within the first 4 weeks. It is a rare disease and the cause is not known but GBS usually follows a viral or bacterial infection. It can affect any age but the incidence increases with age and men are more commonly affected than women. GBS is considered an acute illness. CIDP is the term used for the most chronic cases.
Links syndrome
Relevant Occupations
Expected Prognosis
GBS can be devastating because of its sudden and unexpected onset. Most patients (80-90%) make a full recovery from GBS. Many spend 3 months or more in hospital and may take a year to recover. Some patients do not recover completely and have residual weakness, numbness and occasional pain.
Related Interventions